LEXINGTON, Mass., Jan. 20, 2022 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that James Dentzer,
President and Chief Executive Officer, will participate in the
following upcoming conferences:
- B. Riley Virtual Oncology Conference, Thursday, January 27, 2022 at 1:30 p.m. ET
- SVB Leerink 11th Annual Global Healthcare
Conference, Friday, February 18, 2022
at 11:20 a.m. ET
Live webcasts of the presentations will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. Archived replays of the
webcasts will be available on the Curis website for 90 days
following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1/2 trial in patients with
non-Hodgkin lymphoma both as a monotherapy and in combination with
BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a
Phase 1/2 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes, for which it has received Orphan Drug
Designation from the U.S. Food and Drug Administration. In
addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody, which is
currently undergoing testing in a Phase 1 trial in patients with
solid tumors. Curis is also party to a collaboration with
Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis' website at
www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-301464302.html
SOURCE Curis, Inc.